Spectrum Clinical Research, Inc.

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer
https://clinicaltrials.gov/ct2/show/NCT04404361

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer - Full Text View - ClinicalTrials.gov PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer - Full Text View.

New clinical trial opportunity. For more information, please call 443-798-2670.

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes - Full Text View - ClinicalTrials.gov A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes - Full Text View.

Managing High Potassium

With heart failure, this is a difficult thing to do. Consider the DIAMOND study.

www.DiamondStudy.org

SELECT is a clinical study involving approximately 17,500 people from 41 countries worldwide.

The SELECT study is being done to see if semaglutide can reduce the risk of cardiovascular events such as heart attack or stroke. Previous studies of semaglutide have shown that using semaglutide reduced the risk of cardiovascular events in some people with type 2 diabetes. Semaglutide is already approved in some countries at a lower dose, to treat type 2 diabetes. The SELECT study will examine the effect of semaglutide in people with established cardiovascular disease and obesity or overweight.

For more information, please call us at 443-798-2670.

CLEAR Outcomes Study

A study for people with High Cholesterol

People who are unable to take statin medications due to side effects may be eligible for a clinical research study.

This study is being conducted to evaluate the safety and effectiveness of an investigational medication that may help to reduce the occurrence of major Cardiovascular Disease (CVD) events such as heart attacks and strokes in patients with or at risk for CVD, who are also statin intolerant.

You may qualify if you:
• Are 18 years of age or older
• Have a history of, or are at high risk for Cardiovascular Disease (CVD)
• Are statin intolerant (have not been able to tolerate one or more statins),
• Meet additional study criteria.

For more information, please call (443) 798-2670

SELECT is a clinical study involving approximately 17,500 people from 41 countries worldwide.

The SELECT study is being done to see if semaglutide can reduce the risk of cardiovascular events such as heart attack or stroke. Previous studies of semaglutide have shown that using semaglutide reduced the risk of cardiovascular events in some people with type 2
diabetes. Semaglutide is already approved in some countries at a lower dose, to treat type 2 diabetes. The SELECT study will examine the effect of semaglutide in people with established cardiovascular disease and obesity or overweight.

For more information, please call us at 443-798-2670.

The Spectrum research team at Maryland Cardiovascular Specialists with our fearless P.I. - Dr. Carlos Ince.

CLEAR Outcomes Study

A study for people with High Cholesterol

People who are unable to take statin medications due to side effects may be eligible for a clinical research study.

This study is being conducted to evaluate the safety and effectiveness of an investigational medication that may help to reduce the occurrence of major Cardiovascular Disease (CVD) events such as heart attacks and strokes in patients with or at risk for CVD, who are also statin intolerant.

You may qualify if you:
• Are 18 years of age or older
• Have a history of, or are at high risk for Cardiovascular Disease (CVD)
• Are statin intolerant (have not been able to tolerate one or more statins),
• Meet additional study criteria.

For more information, please call (443) 798-2670 ext. 1.

Our Actively Enrolling Clinical Trials

Diabetes Mellitus

​Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Heart Disease

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

​Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Hyperlipidemia
​
A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

Heart Failure

A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER)

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (Dapa-HF)

A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF): (EMPEROR-Preserved)

Efficacy and Safety of Empagliflozin Compared to Placebo in Patients With Heart Failure With Reduced Ejection Fraction: (EMPEROR-Reduced)

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction (PERSPECTIVE)

Myocardial Infarction

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Peripheral Vascular Disease

​Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Stroke

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

For more information, please call 443-798-2670 ext. 1

Happy Thanksgiving!

Migraine Headache Clinical Trial

Heart Failure Clinical Trial

Have You or a Loved One Received Care for Memory Impairment?

Currently enrolling migraine trial in Baltimore metro area. For more information, please call (800) 725-4760.

Actively Enrolling Clinical Trials

Diabetes Mellitus

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of ertugliflozin (PF-04971729) as Compared with Placebo on the Occurrence of Cardiovascular Events in subjects with Type 2 Diabetes Mellitus and Established vascular disease

A double blind placebo controlled study to evaluate the effects of Bexagliflozin on haemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events. Bexagliflozin Efficacy and Safety Trial (BEST)

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridema (STRENGTH)

Heart Disease

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridema (STRENGTH)

A double blind placebo controlled study to evaluate the effects of Bexagliflozin on haemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events. Bexagliflozin Efficacy and Safety Trial (BEST)

Hyperlipidemia
​
A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridema (STRENGTH)

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

Heart Failure

A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER)

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)

A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction (PARAGON-HF)

A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction (PERSPECTIVE)

Migraine Headache

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Myocardial Infarction

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridema (STRENGTH)​

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

Peripheral Vascular Disease

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridema (STRENGTH)

A double blind placebo controlled study to evaluate the effects of Bexagliflozin on haemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events. Bexagliflozin Efficacy and Safety Trial (BEST)

Stroke

​ A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridema (STRENGTH)

A double blind placebo controlled study to evaluate the effects of Bexagliflozin on haemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events. Bexagliflozin Efficacy and Safety Trial (BEST)

For more information call: (443) 798-2670

Actively Enrolling Clinical Trials

Heart Disease

The Evaluation of Bococizumab in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk (CARMELINA)

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With Atrial Fibrillation That Undergo a PCI With Stenting (REDUAL-PCI)

Hyperlipidemia

The Evaluation of Bococizumab in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridema (STRENGTH)

Myocardial Infarction

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS REGISTRY)

The Evaluation of Bococizumab in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Heart Failure

A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER)

A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction (PARAGON-HF)

Peripheral Vascular Disease

The Evaluation of Bococizumab in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk (CARMELINA)

Stroke

The Evaluation of Bococizumab in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk (CARMELINA)

Diabetes Mellitus

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk (CARMELINA)

A “Real World” to assess the clinical and health outcomes of Toujeo® compared to commercially available basal insulins for initiation of therapy in insulin naïve patients with uncontrolled type 2 diabetes mellitus

Gout

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

For more information please call (443) 798-2670.

BE A PART OF THE FUTURE IN DIABETES RESEARCH...

If you are an adult with type 2 diabetes mellitus, you may be eligible to take part in a clinical research study called CARMELINA.

The purpose of the CARMELINA Study is to look at the impact of an investigational drug called linagliptin on the long-term occurrence of selected complications of cardiovascular disease (e.g. stroke or heart attack) in people with type 2 diabetes mellitus receiving standard of care.

You may be eligible to take part in the CARMELINA Study if:

✔ you are 18 years of age or older

✔ you have been diagnosed with type 2 diabetes mellitus

✔ you have been receiving a stable dose of antidiabetic medication for at least 8 weeks or you have not previously received antidiabetic treatment

✔ you have previously had problems with your heart (cardiovascular disease) and/or kidneys (renal disease).

If you participate in the study, you will take the study drug (linagliptin or placebo) once every day. You will be provided with an electronic device called a glucometer to measure your blood sugar levels once every week (or as agreed with your study doctor), or whenever you feel symptoms of your diabetes.

Depending on when you join the study, your participation could last for a period of up to approximately 4.5 years. You will need to visit the study center a number of times so the study doctor can assess your diabetes and overall health. Most study visits will take place every 24 weeks (6 months). The study doctor will tell you when the study will be ending.

For more information about the CARMELINA Study, please contact: (443) 798-2670

Actively Enrolling Clinical Trials

Heart Disease

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease (Reduction of Cardiovascular Events with EPA-Intervention Trial. (REDUCE-IT)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk (CARMELINA)

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With Atrial Fibrillation That Undergo a PCI With Stenting (REDUAL-PCI)

The Evaluation of Bococizumab in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Hyperlipidemia

The Evaluation of Bococizumab in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridema (STRENGTH)

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease (Reduction of Cardiovascular Events with EPA-Intervention Trial. (REDUCE-IT)

Myocardial Infarction

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS REGISTRY)

The Evaluation of Bococizumab in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Heart Failure

A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER)

A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction (PARAGON-HF)

Peripheral Vascular Disease

The Evaluation of Bococizumab in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease (Reduction of Cardiovascular Events with EPA-Intervention Trial. (REDUCE-IT)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk (CARMELINA)

Stroke

The Evaluation of Bococizumab in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk (CARMELINA)

Diabetes Mellitus

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk (CARMELINA)

A “Real World” to assess the clinical and health outcomes of Toujeo® compared to commercially available basal insulins for initiation of therapy in insulin naïve patients with uncontrolled type 2 diabetes mellitus

Gout

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

For more information please call (443) 798-2670.

The Research Team at Maryland Cardiovascular Specialists

The Research Team at Overlea Personal Physicians

The Next Frontier in Cholesterol Lowering?

PCSK9 inhibitors: a major advance in cholesterol-lowering drug therapy - Harvard Health Blog The results of three trials suggest that a new class of drugs called PCSK9 inhibitors may be a major advance in cholesterol-lowering drug therapy.

We are pleased to announce that we are participating in the landmark SPIRE 1 & SPIRE 2 clinical trials involving bococizumab.

The bococizumab Phase 3 program consists of two cardiovascular (CV) outcome studies as well as multiple lipid-lowering studies in more than 22,000 patients.

One of the two CV outcome studies, SPIRE-1, will assess whether lowering LDL-C to levels well below current guideline-recommended targets will lead to further reduction in cardiovascular events. This study includes a high-risk patient population with baseline levels of LDL-C ranging from 70 to 100 mg/dL.

The second CV outcome study, SPIRE-2, will evaluate the efficacy and safety of bococizumab in a range of high-risk patients who have not achieved LDL levels lower than 100 mg/dL despite the use of high-dose statins or who are partially or completely statin intolerant. The Phase 3 program will evaluate the efficacy and safety of 150 mg twice monthly as a starting dose.

For additional information, please contact us 443-298-2670.

Actively Enrolling Clinical Trials

Heart Disease

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease (Reduction of Cardiovascular Events with EPA-Intervention Trial. (REDUCE-IT)

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) (ODYSSEY Outcomes)

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol (ACCENTUATE)

CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk



Hyperlipidemia

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease (Reduction of Cardiovascular Events with EPA-Intervention Trial. (REDUCE-IT)

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) (ODYSSEY Outcomes)

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol (ACCENTUATE)

Myocardial Infarction

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) (ODYSSEY Outcomes)

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol (ACCENTUATE)



Peripheral Vascular Disease

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease (Reduction of Cardiovascular Events with EPA-Intervention Trial. (REDUCE-IT)

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol (ACCENTUATE)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk



Stroke

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol (ACCENTUATE)

Diabetes Mellitus

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol (ACCENTUATE)



Gout

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

OUR ACTIVELY ENROLLING CLINICAL TRIALS:

HEART DISEASE

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS)

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Trial. (REDUCE-IT)

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout Comorbidities (CARES)

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) (ODYSSEY Outcomes)

HYPERLIPIDEMIA

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Trial. (REDUCE-IT)

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) (ODYSSEY Outcomes)

MYOCARDIAL INFARCTION

CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727) (ODYSSEY Outcomes)

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

CONGESTIVE HEART FAILURE

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)

PERIPHERAL VASCULAR DISEASE

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Clinical trial. (REDUCE-IT)

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

STROKE

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

DIABETES MELLITUS

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS)

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

GOUT

Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities (CARES)

Please call (443) 798-2670 for more information.